Hundsberger H1, Koppensteiner A1, Hofmann E1, Ripper D1, Pflüger M1, Stadlmann V2, Klein CT1, Kreiseder B1, Katzlinger M3, Eger A1, Forster F2, Missbichler A2, Wiesner C1. SLAS Discov. 2017 Mar 1:2472555217697435. doi: 10.1177/2472555217697435. [Epub ahead of print]
Celiac disease (CD) is a chronic inflammatory condition caused by the ingestion of gliadin-containing food in genetically susceptible individuals. Undigested peptides of gliadin exert various effects, including increased intestinal permeability and inflammation in the small intestine. Although many therapeutic approaches are in development, a gluten-free diet is the only effective treatment for CD. Affecting at least 1% of the population in industrialized countries, it is important to generate therapeutic options against CD. Here, we describe the establishment of a high-throughput screening (HTS) platform based on AlphaLISA and electrical cell-substrate impedance sensing (ECIS) technology for the identification of anti-inflammatory and barrier-protective compounds in human enterocytes after pepsin-trypsin-digested gliadin (PT-gliadin) treatment. Our results show that the combination of these HTS technologies enables fast, reliable, simple, and label-free screening of IgY antibodies against PT-gliadin. Using this platform, we have identified a new chicken anti-PT-gliadin IgY antibody as a potential anti-CD agent.
AlphaLISA; Caco-2 monolayer; ECIS; anti-gliadin IgY; celiac disease